# Pimobendan Vetmedin Dose: Cardiac Inotrope Dose and MVD Timing


## Key Takeaways

- Pimobendan is an inodilator with positive inotropic and vasodilatory effects, primarily used for canine myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM). Its mechanism involves calcium sensitization of cardiac myofilaments and phosphodiesterase III inhibition.
- The standard oral dose for dogs is 0.2–0.3 mg/kg every 12 hours, administered approximately 1 hour before feeding to optimize absorption. This dose is evidence-based for delaying congestive heart failure in Stage B2 MMVD.
- Initiation of pimobendan is critical in Stage B2 MMVD, defined by echocardiographic evidence of left heart enlargement, as supported by the EPIC study which demonstrated prolonged time to heart failure onset and improved survival.
- High-dose pimobendan (0.5–0.6 mg/kg q12h) has shown potential for more pronounced cardiac reverse remodeling and reduction in NT-proBNP in Stage B2 MMVD, though the standard dose remains the first-line recommendation.
- Diagnostic workup for MMVD includes echocardiography to stage the disease (crucial for determining B2 status) and thoracic radiographs to assess for heart enlargement and signs of congestive heart failure.
- Monitoring therapy involves assessing clinical signs, serial echocardiography to evaluate cardiac remodeling, and monitoring renal function, as pimobendan generally has a neutral effect on glomerular filtration rate.

---

**Direct Answer:** Pimobendan (Vetmedin) is a positive inotrope and vasodilator (an "inodilator") used to manage canine heart disease, specifically myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM). The standard labeled dose is 0.2 to 0.3 mg/kg orally every 12 hours, given approximately 1 hour before feeding. For dogs with preclinical (Stage B2) MMVD, initiating pimobendan at this standard dose is the evidence-based recommendation to delay the onset of congestive heart failure. **Owner Triage Summary:** If your [dog](/knowledge/veterinary-medicine/clinical-methods/dog) has been diagnosed with a heart murmur or heart disease, do not start or adjust pimobendan without veterinary guidance. This medication is prescription-only and requires echocardiographic assessment to determine the correct stage and timing. If your dog is coughing, breathing rapidly at rest, or showing weakness, seek immediate veterinary care, as these can be signs of congestive heart failure.

This article provides a comprehensive, source-grounded review of pimobendan dosing, its role as a cardiac inotrope, and the critical timing of initiation in myxomatous mitral valve disease (MVD). We will cover pharmacology, clinical evidence, dosing protocols, and practical management considerations for veterinarians and informed pet owners.

## At a Glance: Pimobendan Dosing and Indications

| Parameter | Standard Dose (Oral) | High Dose (Oral) | Injectable (IV) | Notes |
| :--- | :--- | :--- | :--- | :--- |
| **Canine Dose** | 0.2–0.3 mg/kg q12h [<a href="#ref-1">1</a>] | 0.5–0.6 mg/kg q12h [<a href="#ref-1">1</a>] | 0.15 mg/kg IV [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>] | Oral dose is label; high dose is experimental but studied. |
| **Feline Dose** | 1.25 mg/[cat](/knowledge/veterinary-medicine/clinical-methods/cat) q12h [<a href="#ref-4">4</a>] | 0.25–0.3 mg/kg q12h (studied) [<a href="#ref-5">5</a>][<a href="#ref-6">6</a>] | 0.15–0.3 mg/kg IV (studied) [<a href="#ref-6">6</a>] | Oral 1.25 mg/cat is common; weight-based studied. |
| **Primary Indication** | Canine MMVD (Stage B2, C, D) | Canine MMVD (Stage B2) | Canine heart failure (acute) | Used for DCM as well [<a href="#ref-7">7</a>]. |
| **Timing of Administration** | 1 hour before feeding | 1 hour before feeding | Given as a bolus or infusion | Food can delay absorption of oral forms. |
| **Key Monitoring** | Echocardiography, NT-proBNP, renal function | Echocardiography, NT-proBNP, renal function | Blood pressure, ECG, cardiac output | Clinical improvement and biomarker trends guide therapy. |

## Understanding Pimobendan: The Cardiac Inotrope

Pimobendan is a benzimidazole-pyridazinone derivative with a dual mechanism of action. It is a positive inotrope (increases the force of heart muscle contraction) and a vasodilator (widens blood vessels). This combination is often described as an "inodilator."

- **Positive Inotropy:** Pimobendan increases the sensitivity of cardiac myofilaments to calcium. This calcium sensitization enhances myocardial contractility without a corresponding increase in intracellular calcium concentration or myocardial oxygen demand, a distinct advantage over traditional inotropes like digoxin or dobutamine [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>].
- **Vasodilation:** Pimobendan also inhibits phosphodiesterase III (PDE3), an enzyme that breaks down cyclic AMP. Inhibition of PDE3 in vascular smooth muscle leads to vasodilation, reducing afterload (the resistance the heart must pump against) [<a href="#ref-8">8</a>]. This dual action improves cardiac output while reducing the workload on the heart.

The active metabolite, O-desmethyl-pimobendan (ODMP), also contributes significantly to the drug's pharmacological effects, particularly after oral administration [<a href="#ref-5">5</a>][<a href="#ref-9">9</a>][<a href="#ref-3">3</a>].

## The Role of Pimobendan in Myxomatous Mitral Valve Disease (MVD)

Myxomatous mitral valve disease (MMVD) is the most common acquired heart disease in dogs, particularly affecting small-breed, older dogs. The disease is characterized by progressive thickening and degeneration of the mitral valve, leading to valve insufficiency (leakage) and, eventually, heart enlargement and failure. Pimobendan is a cornerstone of therapy for this condition.

### ACVIM Staging and Timing of Therapy

The American College of Veterinary Internal Medicine (ACVIM) has established a staging system for MMVD that guides treatment decisions. The timing of pimobendan initiation is critical and is based on this staging.

- **Stage A:** Dogs at high risk for developing MMVD (e.g., Cavalier King Charles Spaniels) but with no structural heart disease.
- **Stage B:** Dogs with a heart murmur and structural heart disease (e.g., valve thickening) but no clinical signs of heart failure.
    - **Stage B1:** Dogs without radiographic or echocardiographic evidence of heart enlargement. Pimobendan is not typically recommended at this stage.
    - **Stage B2:** Dogs with radiographic or echocardiographic evidence of left heart enlargement. This is the key stage where pimobendan has been shown to be highly beneficial, delaying the onset of congestive heart failure.
- **Stage C:** Dogs with current or past clinical signs of congestive heart failure (e.g., coughing, difficulty breathing). Pimobendan is a standard part of therapy.
- **Stage D:** Dogs with refractory heart failure that do not respond to standard Stage C therapy.

### The Evidence for Stage B2 Timing

The decision to start pimobendan in Stage B2 is supported by a landmark study known as the EPIC study. This research demonstrated that initiating pimobendan at a standard dose (0.2–0.3 mg/kg q12h) in dogs with Stage B2 MMVD significantly prolonged the time before the onset of congestive heart failure and improved survival compared to a placebo [<a href="#ref-1">1</a>].

Further research has investigated the effects of standard-dose versus high-dose pimobendan in Stage B2 dogs. A prospective, randomized, double-blinded, placebo-controlled study by Kaplan et al. (2022) examined the effects of standard-dose (0.2–0.3 mg/kg q12h) and high-dose (0.5–0.6 mg/kg q12h) pimobendan on renal and cardiac function in dogs with Stage B2 MMVD [<a href="#ref-1">1</a>]. The study found that high-dose pimobendan significantly reduced N-terminal pro-brain natriuretic peptide (NT-proBNP), left atrial volume (LAV), left ventricular end-diastolic volume (EDV), and end-systolic volume (ESV) compared to placebo. While standard-dose pimobendan also showed favorable trends in these parameters, the changes were not statistically significantly different from placebo in this study, though they were also not significantly different from the high-dose group. Neither dose significantly altered glomerular filtration rate (GFR), suggesting a neutral effect on renal function [<a href="#ref-1">1</a>].

This research highlights the importance of initiating therapy at the correct time (Stage B2) and provides evidence that the standard dose is effective, while higher doses may offer more profound reverse remodeling of the heart.

## Pimobendan Vetmedin Dose: Standard Protocols

The standard, label-recommended dose of pimobendan (Vetmedin) for dogs is **0.2 to 0.3 mg/kg orally every 12 hours** [<a href="#ref-1">1</a>][<a href="#ref-7">7</a>]. This dose is used for managing both MMVD and dilated cardiomyopathy (DCM) [<a href="#ref-7">7</a>].

### Administration Guidelines

- **Timing:** Pimobendan should be administered on an empty stomach, ideally 1 hour before a meal. Food can significantly delay the absorption of the drug, reducing peak plasma concentrations and potentially delaying the onset of its therapeutic effect.
- **Formulations:** Pimobendan is available as chewable tablets in various strengths and, more recently, as an oral solution. A bioequivalence study demonstrated that a 1.5-mg/mL oral solution is bioequivalent to the 5-mg capsules, offering an alternative for dosing accuracy, especially in small dogs [<a href="#ref-10">10</a>]. Custom-compounded formulations may have variable absorption; one study found that experimental capsules with or without citrate had high relative absorption compared to the approved product, but peak concentrations varied [<a href="#ref-11">11</a>]. A study on 3D-printed pimobendan tablets showed they are a viable option for dose individualization, though their absorption profile differs from the commercial product [<a href="#ref-12">12</a>].
- **Injectable Form:** An injectable formulation of pimobendan is available for intravenous (IV) use in hospital settings. The recommended IV dose is 0.15 mg/kg, which produces a rapid inotropic effect and decreased left ventricular end-diastolic pressure (LVEDP) in healthy dogs [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>]. This route is useful for managing acute heart failure when oral administration is not possible.

## High-Dose Pimobendan: Evidence and Clinical Use

The concept of high-dose pimobendan has been explored to determine if doses higher than the label recommendation provide additional benefits, particularly in dogs with severe heart enlargement or refractory heart failure.

### High-Dose in Stage B2 MMVD

As detailed earlier, a study by Kaplan et al. (2022) evaluated high-dose pimobendan (0.5–0.6 mg/kg q12h) in dogs with Stage B2 MMVD [<a href="#ref-1">1</a>]. The results showed that this higher dose led to significant reductions in cardiac size (LAV, EDV, ESV) and NT-proBNP levels compared to placebo. This suggests that high-dose pimobendan may induce more pronounced reverse remodeling of the heart in preclinical disease.

However, it is crucial to note that this study was short-term (7-10 days) and did not find a statistically significant difference between the standard-dose and high-dose groups for these parameters. Therefore, while high-dose pimobendan is biologically active and may be beneficial, the standard dose remains the first-line recommendation. The decision to use a higher dose should be made on a case-by-case basis by a veterinary cardiologist, considering the individual patient's risk factors and response to therapy.

## Pimobendan in Feline Cardiology

While pimobendan is not FDA-approved for use in cats, it is used off-label to manage heart disease, particularly hypertrophic cardiomyopathy (HCM) and other cardiomyopathies, especially when congestive heart failure is present.

### Feline Dosing and Evidence

- **Standard Oral Dose:** A common empirical dose is 1.25 mg per cat every 12 hours [<a href="#ref-4">4</a>][<a href="#ref-13">13</a>]. This dose has been shown to increase left atrial fractional shortening in cats with HCM, suggesting improved atrial function without exacerbating left ventricular outflow tract obstructions [<a href="#ref-4">4</a>].
- **Weight-Based Dosing:** A study by Sugimoto et al. (2022) investigated repeated-dose pharmacodynamics in healthy cats and found that doses of 0.25 mg/kg and 0.5 mg/kg q12h significantly increased cardiac systolic function, with a correlation between plasma drug concentrations and effect [<a href="#ref-5">5</a>]. This suggests that weight-based dosing can be effective.
- **Injectable Form:** An intravenous dose of 0.15 to 0.3 mg/kg has been shown to increase fractional shortening, peak systolic velocity, and cardiac output in healthy sedated cats [<a href="#ref-6">6</a>].

Pimobendan has also been shown to have positive effects on right ventricular and atrial function in healthy cats, as evidenced by increased right ventricular fractional shortening and tricuspid annular motion after a single 1.25 mg dose [<a href="#ref-13">13</a>].

## Pimobendan in Other Species

Pimobendan's use is not limited to dogs and cats. It has been investigated in other species, though its use is not standard.

- **Horses:** A study on healthy horses found that a single oral dose of 0.5 mg/kg resulted in very low plasma concentrations of pimobendan, and the active metabolite O-desmethyl-pimobendan was not detected. This suggests poor oral bioavailability in horses, making it unlikely to be an effective treatment [<a href="#ref-14">14</a>].
- **Sharks:** An interesting case report documented the successful use of oral pimobendan (0.3 mg/kg q48h, later increased to 0.5 mg/kg three times a week) to treat suspected dilated cardiomyopathy in two leopard sharks, with significant improvement in cardiac function and clinical signs [<a href="#ref-15">15</a>].

## Clinical Evidence and Pharmacodynamics

The clinical benefits of pimobendan are well-documented across various studies.

- **In Canine DCM:** A study by Abbott-Johnson et al. (2021) investigated the acute effects of pimobendan (0.25 mg/kg) in dogs with tachycardia-induced DCM. They found that pimobendan significantly increased systolic function and improved other hemodynamic parameters, reinforcing its role as a first-line inotrope for DCM [<a href="#ref-7">7</a>].
- **In Canine Pulmonary Hypertension:** Pimobendan has been shown to improve left and right ventricular function without increasing pulmonary arterial pressure (PAP) in dogs with chronic pulmonary hypertension. This is a significant advantage over catecholamines like dobutamine and dopamine, which can worsen PAP [<a href="#ref-8">8</a>].
- **During Anesthesia:** Oral pimobendan (0.3 mg/kg) given as a pre-anesthetic medication has been shown to preserve left ventricular systolic and myocardial function during isoflurane anesthesia, comparable to the effects of IV pimobendan [<a href="#ref-16">16</a>].
- **In Acute Respiratory Acidosis:** A study on dogs with acute respiratory acidosis found that IV pimobendan improved cardiac output and other cardiovascular parameters, suggesting it may be effective even in acidotic states [<a href="#ref-17">17</a>].
- **Intramuscular Administration:** A pilot study investigated the effects of intramuscular (IM) pimobendan in healthy dogs. The results showed that IM administration increased stroke volume and cardiac output and decreased systemic vascular resistance, although the onset of effect was slower than with IV administration [<a href="#ref-18">18</a>].

## Diagnostic Workup and Monitoring

Before starting pimobendan, a thorough diagnostic workup is essential to confirm the diagnosis, stage the disease, and rule out other causes of clinical signs.

### Essential Diagnostics

1.  **Physical Examination:** Auscultation for a heart murmur, assessment of mucous membrane color, capillary refill time, and pulse quality.
2.  **Echocardiography:** This is the gold standard for diagnosing and staging MMVD. It allows for measurement of the left atrial-to-aortic root ratio (LA/Ao), left ventricular internal diameter in diastole (LVIDd), and assessment of valve morphology and function. These measurements are critical for determining if a dog is in Stage B2 and thus a candidate for pimobendan therapy.
3.  **Thoracic Radiographs (X-rays):** These are used to assess for heart enlargement and to detect signs of congestive heart failure, such as pulmonary edema or pleural effusion.
4.  **Biomarkers:** N-terminal pro-brain natriuretic peptide (NT-proBNP) is a blood test that can help differentiate cardiac from non-cardiac causes of respiratory signs and can be used to monitor response to therapy. High-dose pimobendan has been shown to significantly lower NT-proBNP levels [<a href="#ref-1">1</a>].
5.  **Baseline Bloodwork:** A complete blood count and serum biochemistry profile, including renal parameters, are recommended to assess overall health and establish baseline values, especially since heart failure can affect kidney function.

### Monitoring Therapy

- **Clinical Signs:** Monitor for improvement in exercise tolerance, appetite, and respiratory effort. Owners should be educated on how to count their dog's resting respiratory rate at home, as an increased rate (>30 breaths per minute) is an early sign of congestive heart failure.
- **Echocardiography:** Repeat echocardiograms are recommended to assess cardiac remodeling and response to therapy. The study by Kaplan et al. (2022) showed that pimobendan can lead to significant reductions in heart size (LAV, EDV, ESV) [<a href="#ref-1">1</a>].
- **Renal Function:** While pimobendan appears to have a neutral effect on GFR in dogs with Stage B2 MMVD [<a href="#ref-1">1</a>], monitoring renal parameters is prudent, especially when used in combination with diuretics like furosemide or torsemide in heart failure stages.

## Safety, Adverse Effects, and Contraindications

Pimobendan is generally well-tolerated in dogs and cats.

- **Common Adverse Effects:** Gastrointestinal signs such as vomiting, diarrhea (or diarrhoea), and anorexia can occur, but are often transient. In a study on healthy cats, repeated doses of pimobendan were well-tolerated with no significant adverse effects reported [<a href="#ref-5">5</a>].
- **Cardiovascular Effects:** In healthy cats, IV pimobendan at higher doses (0.15–0.3 mg/kg) increased heart rate, but did not significantly change blood pressure [<a href="#ref-6">6</a>]. In dogs with pulmonary hypertension, pimobendan did not increase PAP, unlike catecholamines [<a href="#ref-8">8</a>].
- **Contraindications:** Pimobendan is contraindicated in cases of hypertrophic cardiomyopathy (HCM) where outflow tract obstruction is a concern, as its inotropic effect could potentially worsen the obstruction. However, a study in cats with HCM found that a single dose of 1.25 mg did not exacerbate left ventricular outflow tract obstructions [<a href="#ref-4">4</a>]. Caution is advised in patients with aortic stenosis or other conditions where increased myocardial oxygen demand could be detrimental.
- **Overdose:** There is no specific antidote for pimobendan overdose. Treatment is supportive and symptomatic.

## Unsafe Home Remedies and Owner Misconceptions

It is critical to address common owner misconceptions and discourage unsafe practices.

- **No Over-the-Counter Alternatives:** There are no effective over-the-counter supplements or remedies that can replace the proven benefits of pimobendan. While supplements like omega-3 fatty acids may have some supportive benefits, they do not treat the underlying heart disease.
- **Do Not Adjust Dosing Without Veterinary Guidance:** Owners should never adjust the dose or frequency of pimobendan without consulting their veterinarian. Giving too much can cause adverse effects, while giving too little may be ineffective.
- **Do Not Stop Abruptly:** Pimobendan should not be stopped abruptly, especially in dogs with heart failure, as this can lead to a rapid decompensation and recurrence of clinical signs.
- **Compounded Medications:** While compounded pimobendan may be more affordable, its absorption and efficacy can vary significantly compared to the approved brand-name product (Vetmedin) [<a href="#ref-11">11</a>]. A study on compounded powdered medications for MMVD found that a fixed-dose combination tablet was more effective than the compounded powder, possibly due to better dosing accuracy and stability [<a href="#ref-19">19</a>]. It is important to discuss the pros and cons of compounded versus brand-name medications with your veterinarian.

## Prevention and Prognosis

- **Prevention:** MMVD is a degenerative disease that cannot be prevented. However, early detection through regular veterinary check-ups, including auscultation for heart murmurs, is crucial. For dogs diagnosed with Stage B2 MMVD, the timely initiation of pimobendan is the single most effective intervention to delay the onset of heart failure and improve quality of life [<a href="#ref-1">1</a>].
- **Prognosis:** The prognosis for dogs with MMVD is highly variable and depends on the stage of the disease at diagnosis. Dogs in Stage B2 that receive pimobendan have a significantly prolonged time to the onset of congestive heart failure. With appropriate therapy, many dogs can live comfortably for years after diagnosis.

## Limitations and When to Contact a Veterinarian

This article provides a detailed overview of pimobendan dosing and timing for MVD. However, it is not a substitute for professional veterinary advice. The information presented here cannot predict the specific outcome for any individual pet. Breed-specific variations, concurrent diseases, and individual responses to therapy can significantly influence the course of the disease and the optimal treatment plan.

**You should contact your veterinarian immediately if your dog or cat exhibits any of the following emergency red flags:**

- **Difficulty breathing or rapid breathing at rest (greater than 30 breaths per minute).**
- **Coughing, especially if it is persistent or productive.**
- **Weakness, collapse, or fainting episodes.**
- **Pale or blue-tinged gums.**
- **Sudden onset of abdominal distension (potentially indicating fluid accumulation).**
- **Inability to stand or walk.**

These signs can indicate the onset of congestive heart failure and require immediate veterinary intervention.

## Frequently Asked Questions

**1. What is the standard dose of pimobendan (Vetmedin) for dogs?**
The standard dose of pimobendan for dogs is 0.2 to 0.3 mg/kg, given orally every 12 hours, ideally on an empty stomach [<a href="#ref-1">1</a>][<a href="#ref-7">7</a>].

**2. When should I start giving my dog pimobendan for mitral valve disease?**
Pimobendan should be started when your dog is diagnosed with Stage B2 myxomatous mitral valve disease, which is characterized by heart enlargement on an echocardiogram or X-ray, even if they are not showing clinical signs [<a href="#ref-1">1</a>].

**3. Can I give my cat pimobendan?**
Yes, pimobendan is used off-label in cats, often at a dose of 1.25 mg per cat every 12 hours, to manage certain types of heart disease, particularly when heart failure is present [<a href="#ref-4">4</a>][<a href="#ref-13">13</a>].

**4. What is the difference between standard-dose and high-dose pimobendan?**
Standard-dose pimobendan is 0.2-0.3 mg/kg q12h. High-dose pimobendan, studied at 0.5-0.6 mg/kg q12h, has been shown to cause more significant reductions in heart size and NT-proBNP levels in dogs with Stage B2 MMVD, but the standard dose remains the first-line therapy [<a href="#ref-1">1</a>].

**5. How long does it take for pimobendan to start working?**
When given intravenously, pimobendan's inotropic effect is seen within minutes [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>]. When given orally, its effects are typically seen within 1 to 2 hours, so it is often given 1 hour before meals to ensure rapid absorption.

**6. What are the common side effects of pimobendan?**
The most common side effects are gastrointestinal, such as vomiting, diarrhea (or diarrhoea), and loss of appetite. These are often mild and transient [<a href="#ref-5">5</a>].

**7. Is pimobendan safe for dogs with kidney disease?**
A study in dogs with Stage B2 MMVD found that pimobendan had no significant effect on glomerular filtration rate (GFR), suggesting it is safe for the kidneys. However, monitoring renal function is still recommended, especially in patients on other medications [<a href="#ref-1">1</a>].

**8. Can pimobendan be given with other heart medications?**
Yes, pimobendan is often used in combination with other heart medications such as diuretics (furosemide, torsemide), ACE inhibitors (enalapril), and spironolactone. A fixed-dose combination tablet containing these drugs has been shown to be effective and safe [<a href="#ref-19">19</a>].

**9. What should I do if I miss a dose of pimobendan?**
If you miss a dose, give the next scheduled dose at the normal time. Do not give a double dose to make up for the missed one. If you have questions, contact your veterinarian.

**10. Are compounded pimobendan formulations as effective as Vetmedin?**
Compounded formulations may have variable absorption and efficacy compared to the approved brand-name product Vetmedin. Studies have shown that the pharmacokinetics of compounded products can differ significantly [<a href="#ref-11">11</a>]. It is important to discuss the potential risks and benefits with your veterinarian.

<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "What is the standard dose of pimobendan (Vetmedin) for dogs?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The standard dose of pimobendan for dogs is 0.2 to 0.3 mg/kg, given orally every 12 hours, ideally on an empty stomach."
      }
    },
    {
      "@type": "Question",
      "name": "When should I start giving my dog pimobendan for mitral valve disease?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Pimobendan should be started when your dog is diagnosed with Stage B2 myxomatous mitral valve disease, which is characterized by heart enlargement on an echocardiogram or X-ray, even if they are not showing clinical signs."
      }
    },
    {
      "@type": "Question",
      "name": "Can I give my cat pimobendan?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes, pimobendan is used off-label in cats, often at a dose of 1.25 mg per cat every 12 hours, to manage certain types of heart disease, particularly when heart failure is present."
      }
    },
    {
      "@type": "Question",
      "name": "What is the difference between standard-dose and high-dose pimobendan?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Standard-dose pimobendan is 0.2-0.3 mg/kg q12h. High-dose pimobendan, studied at 0.5-0.6 mg/kg q12h, has been shown to cause more significant reductions in heart size and NT-proBNP levels in dogs with Stage B2 MMVD, but the standard dose remains the first-line therapy."
      }
    },
    {
      "@type": "Question",
      "name": "How long does it take for pimobendan to start working?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "When given intravenously, pimobendan's inotropic effect is seen within minutes. When given orally, its effects are typically seen within 1 to 2 hours, so it is often given 1 hour before meals to ensure rapid absorption."
      }
    },
    {
      "@type": "Question",
      "name": "What are the common side effects of pimobendan?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The most common side effects are gastrointestinal, such as vomiting, diarrhea (or diarrhoea), and loss of appetite. These are often mild and transient."
      }
    },
    {
      "@type": "Question",
      "name": "Is pimobendan safe for dogs with kidney disease?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "A study in dogs with Stage B2 MMVD found that pimobendan had no significant effect on glomerular filtration rate (GFR), suggesting it is safe for the kidneys. However, monitoring renal function is still recommended, especially in patients on other medications."
      }
    },
    {
      "@type": "Question",
      "name": "Can pimobendan be given with other heart medications?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes, pimobendan is often used in combination with other heart medications such as diuretics (furosemide, torsemide), ACE inhibitors (enalapril), and spironolactone. A fixed-dose combination tablet containing these drugs has been shown to be effective and safe."
      }
    }
  ]
}
</script>

## Related Clinical & Scientific Guides

* [Drontal Plus Dewormer: Broad-Spectrum Dose Guide by Weight](/knowledge/veterinary-medicine/calculators-clinical-tools/drontal-plus-dewormer-broad-spectrum-dose-guide-by-weight)
* [Panacur Fenbendazole Dewormer: Dog Fecal Parasite Treatment Schedule](/knowledge/veterinary-medicine/calculators-clinical-tools/panacur-fenbendazole-dewormer-dog-fecal-parasite-treatment-schedule)
* [Prednisolone for Cats: Feline Safe Steroid Dose and Autoimmune](/knowledge/veterinary-medicine/calculators-clinical-tools/prednisolone-for-cats-feline-safe-steroid-dose-and-autoimmune)